Superquin

Quick links to important sections

Superquin

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Superquin

Quick Facts

Property Description
Active ingredient Prulifloxacin (INN)
Form Oral Tablet
Pharmacological class Fluoroquinolone Antibiotic
Common Use Type Anti-infective agent
Origin Synthetic

Superquin: Classification and Active Ingredient

Superquin is a trade name for a prescription-only synthetic anti-infective agent containing the active component Prulifloxacin, a compound classified within the potent fluoroquinolone family of antibiotics. This medicine is supplied as a single-ingredient oral tablet for systemic administration, distinguishing it from topical or combination preparations. The fluoroquinolone class is characterized by its unique chemical structure and functions as a broad-spectrum and bactericidal agent.

Prulifloxacin's classification is clinically recognized, and its synthetic origin marks it as a modern, third-generation fluoroquinolone. This class of medicine is designed to neutralize bacteria throughout the body by targeting internal processes, and the drug is useful because of its ability to fight a wide range of bacteria. The active substance is generally manufactured by companies such as Chiesi Farmaceutici S.p.A. and is widely recognized in several European and Asian markets.

Prulifloxacin: Prodrug Nature and Bactericidal Action

Prulifloxacin is specifically engineered as a prodrug, meaning the molecule itself is biologically inactive upon oral ingestion but undergoes an essential transformation into the highly effective active metabolite, Ulifloxacin. This conversion, which occurs primarily through hydrolysis by esterases in the body, is the definitive requirement for the drug's action.

Ulifloxacin is the compound that performs the definitive bactericidal action of Superquin. The general purpose of this medicine is to eliminate susceptible bacterial pathogens, achieving this by disrupting core bacterial functions related to genetic material. The specialized prodrug design is a key feature intended to enhance the delivery or stability of the fully active agent. The active metabolite is responsible for the drug's ability to neutralize bacteria.

Distinguishing Features of This Fluoroquinolone

The efficacy of Superquin stems from its specific mechanism, which involves the highly targeted inhibition of two vital bacterial enzymes: DNA gyrase and topoisomerase IV. These enzymes are essential for bacteria to accurately manage their chromosomal structure and are required for processes like DNA replication. By blocking these critical enzymes, Ulifloxacin prevents bacterial cells from surviving or multiplying. This specialized mode of action underpins the drug's general utility as an agent for overcoming bacterial proliferation.

What side effects are possible with Superquin?

Possible Side Effects and Safety Information

Superquin (Prulifloxacin) is a fluoroquinolone antibiotic associated with both commonly reported side effects and serious, potentially disabling class-specific adverse reactions documented in regulatory sources.

Adverse Reaction Scope

The safety profile is structured around System-Organ-Classes, with effects ranging from frequent to very rare.

Category Examples (Officially Documented)
Common Effects Gastrointestinal disturbances (nausea, diarrhoea, abdominal pain, vomiting), headache, dizziness, and skin rash.
System-Organ Classes Musculoskeletal, Nervous System, Psychiatric, Cardiac, Gastrointestinal, Skin, and Metabolism disorders.

Serious Adverse Reactions

The most serious, though less frequent, adverse reactions documented by regulatory agencies often affect the nervous and musculoskeletal systems and can be potentially long-lasting or irreversible:

  • Tendinitis and Tendon Rupture: A major concern for the fluoroquinolone class. The risk is noted to be increased in patients over 60, those with renal impairment, and those receiving concomitant systemic corticosteroids.
  • Peripheral Neuropathy: Nerve damage (e.g., pain, tingling, numbness, weakness) that may be sensory or sensorimotor.
  • Central Nervous System (CNS) and Psychiatric Effects: Including confusion, hallucinations, anxiety, depression, and, rarely, suicidal thoughts, which can occur after the first dose.
  • Blood Glucose Disturbances: Risk of both low (hypoglycaemia) and high (hyperglycaemia) blood sugar levels, noted particularly for diabetic patients.
  • Cardiac Risk: Potential for prolongation of the QT interval, a cardiac risk that may lead to abnormal heart rhythm.

Population-Specific Safety Considerations

The official label states that serious adverse reactions, particularly tendon injuries, may occur within 48 hours of starting the medicine or up to several months after discontinuation. Use is generally not recommended or is contraindicated in the pediatric population, during pregnancy, and for individuals with a known history of tendon disorders related to quinolones.

Resulting Safety Structure

The regulatory safety summary highlights that the most significant safety concerns are related to the seriousness and potential for permanence of effects on the nervous and musculoskeletal systems, regardless of the medicine's primary purpose. The profile requires careful consideration of individual risk factors and timing of adverse event onset.

Overdose and Emergency Response

Overdosage with Superquin (Prulifloxacin) requires immediate action based on documented regulatory guidance. Acute overexposure may be associated with manifestations such as nausea, vomiting, and epigastric pain. The official regulatory labeling for the fluoroquinolone drug class highlights the potential for severe systemic outcomes affecting the Central Nervous System (CNS), cardiovascular, and metabolic systems.

Life-threatening complications documented for the drug class may include seizures, cardiac arrhythmia associated with QT interval prolongation, and profound hypoglycemia that can progress to coma. Regulatory documents mandate that acute overdosage be managed with careful observation and supportive treatment. Procedural steps such as gastric lavage may be required to empty the stomach, as no specific pharmacological antidote is formally documented as being available.

Urgent medical attention must be sought immediately if any serious signs develop, including loss of consciousness, abnormally rapid heart rhythm, or sudden, severe chest or back pain. The official profile further notes that special consideration must be given to high-risk groups; specifically, elderly patients and those with diabetes are documented as being at an increased risk of severe hypoglycemia. Treatment must be stopped immediately upon the first sign of severe tendon or joint pain.

Therapeutic Uses of Superquin

What Superquin Treats: Main Uses and Benefits

Superquin is an agent used to address infection that is commonly used to address specific bacterial infections, providing supportive relief that may assist with symptom management and functional stability in acute clinical situations. The drug is relevant for managing conditions such as uncomplicated and complicated urinary tract infections, acute exacerbation of chronic bronchitis, and acute bacterial rhinosinusitis.

This medication is applied across domains where short-term symptomatic assistance is needed to manage the fever, pain, and inflammation associated with these infections. This medicine is generally applied across the genitourinary domain to ease clusters of symptoms and may be commonly used when patients with established chronic bronchitis experience a sudden, acute bacterial exacerbation. It may assist with maintaining functional stability when symptoms become more noticeable and interfere with routine activities.

“It is considered relevant in clinical settings marked by heightened symptom distress, offering symptomatic relief that may help patients cope more steadily with symptom fluctuations.”


Quick Fact: Therapeutic Domains

Therapeutic Domain Conditions and Symptoms Addressed
Genitourinary Comfort Used in conditions where painful urination (dysuria) and pelvic discomfort are present.
Respiratory Support Applied when pronounced symptoms like cough and purulent sputum affect stability in chronic bronchitis.
Systemic Symptom Relief Relevant for managing fever and localized pain associated with acute bacterial episodes.

Eligibility and Restrictions for Use

Superquin (Prulifloxacin) eligibility is strictly defined by regulatory labeling, limiting its use to specific adult populations. The medicine is formally indicated only for adults 18 years of age and older.

Absolute Contraindications

Use is absolutely prohibited in the following groups:

  • Children and adolescents under 18 years of age.
  • Women who are pregnant or breastfeeding (lactating).
  • Patients with documented hypersensitivity to any quinolone antibiotic.
  • Patients with a history of tendon diseases linked to prior quinolone use.
  • Individuals with rare hereditary metabolic disorders such as galactose intolerance.

Restricted Use and Special Caution

Use is not recommended in individuals with a known history of myasthenia gravis. Special caution is mandated for several high-risk groups, including:

  • Elderly patients (over 60).
  • Individuals with renal impairment or who are solid organ transplant recipients.
  • Patients with certain Central Nervous System (CNS) disorders or a history of aortic aneurysm/dissection.

This profile strictly defines the limited, eligible user population as documented in official regulatory sources.

What should I know about interactions with other medicines?

The official interaction profile for Superquin is structured around two key areas: the potential for reduced drug absorption and specific pharmacodynamic risks documented in regulatory labels.

Co-administration with multivalent cation-containing preparations, such as aluminum- and magnesium-containing antacids or products containing iron and calcium, significantly reduces the absorption of Superquin. Regulatory documents require a mandatory time separation: Superquin must be administered two hours before or at least four hours after these preparations. The co-ingestion of milk also decreases the drug's overall exposure (Area Under the Curve or AUC) in the body.

Specific pharmacodynamic and exposure risks are noted for several medicines. Concomitant use with corticosteroids should be avoided due to the officially documented risk of tendinitis and tendon rupture. The administration with certain NSAIDs, such as Fenbufen, carries an increased risk of seizures. Hypoglycemic agents are also noted to increase the risk of hypoglycemia when co-administered. Additionally, Superquin may enhance the effects of oral anticoagulants, like Warfarin, and cause a slight decrease in the clearance of Theophylline. The regulatory profile also notes that Probenecid decreases the urinary excretion of Prulifloxacin, and co-administration with Nicardipine has been noted to potentially potentiate phototoxicity.

Mechanism of Action

Target Enzyme Inhibition and Prodrug Activation

The action of Superquin begins with the conversion of the parent compound, Prulifloxacin, into its biologically active metabolite, Ulifloxacin, a process mediated by host esterases. Ulifloxacin then performs a targeted action by inhibiting two essential bacterial enzymes: DNA gyrase and Topoisomerase IV.


Molecular Cascade and Bactericidal Action

Ulifloxacin traps these essential enzymes onto the bacterial DNA (cleavage complex stabilization), transforming them into toxic agents that induce irreversible DNA double-strand breaks. This irreversible molecular damage triggers a programmed cell death cascade, resulting in the bactericidal outcome against susceptible organisms.


Mechanism Constraints and Resistance

The functional range of this mechanism is constrained by bacterial countermeasures, specifically genetic mutations that structurally weaken drug binding to the target enzymes. Additionally, bacterial efflux pumps actively expel Ulifloxacin, reducing the intracellular concentration required to initiate the final molecular cascade.

Dosage and Administration Information

The medicine Superquin, containing the active substance Prulifloxacin, is administered exclusively via the oral route as a film-coated tablet. The established dosing schedule for adults is a fixed 600 mg dose taken once daily, which is consistent across most approved indications.

The duration of use is variable, ranging from a single dose for certain uncomplicated urinary tract infections up to a maximum course of 10 days for more complicated infections, depending on the specific condition. This once-daily administration pattern defines the primary use schedule of the medicine.

Administration Constraints and Adjustments

Specific procedural requirements govern the intake of the tablet to ensure consistent absorption. Administrative guidelines specify that the dose be separated by at least 2 hours before or 4 hours after the ingestion of any products containing aluminum, magnesium, iron, or calcium—such as antacids and mineral supplements. Concomitant intake with milk or calcium-fortified beverages is also avoided due to potential interference with absorption.

For specific populations, dose adjustment rules apply. In adults with severe renal impairment (creatinine clearance less than 30 mL/min), the dose is reduced to 300 mg once daily; the tablet can be divided to achieve this dose. Use of the medicine is not recommended in the pediatric population (children and adolescents under 18). If a dose is missed, standard protocols indicate the user should take the dose immediately unless it is close to the next scheduled dose, in which case the missed dose is skipped.

Recent Clinical Evidence

Recent Clinical Evidence

Omega-3 Fatty Acids and Rheumatoid Arthritis (RA)

Research evidence has examined whether taking an omega-3 supplement is associated with joint pain and morning stiffness in people with rheumatoid arthritis (RA). These associations have been explored in multiple studies, and the supplement is often researched as an adjunct therapy.

Key Study Findings

Morning Stiffness and Pain Relief

Meta-analyses have examined the duration of morning stiffness and reported an average difference of 30 minutes when a specific dosage was studied. Studies have explored whether the supplement may influence disease markers.

Anti-Inflammatory Markers (CRP and ESR)

Randomized Controlled Trials (RCTs) have examined the impact of omega-3 supplementation on C-Reactive Protein (CRP) and Erythrocyte Sedimentation Rate (ESR), which are markers of inflammation.

  • One large-scale trial reported a statistically significant difference in CRP levels at six months compared to the control group.
  • Another RCT explored the relationship between baseline fish consumption and changes in ESR over one year.

Dosage and Tolerability

The standard daily dosage range most frequently evaluated in clinical trials was specific. This dosage was the one most frequently evaluated, though studies documented occurrences of minor stomach upset.

Studies have evaluated the evidence for doses above 2g/day in populations with a history of bleeding or those taking blood-thinning medications.

Omega-3 in Early-Stage RA

A study of 150 patients with early-stage RA reported a change in joint tenderness compared to placebo. The research examined whether introducing the supplement early in the disease course was associated with the use of conventional therapies.

Overall, omega-3 fatty acids are a frequently researched area in inflammatory joint diseases.

Key Studies & References

  1. A meta-analysis of the analgesic effects of omega-3 polyunsaturated fatty acid supplementation for inflammatory joint pain (Morning Stiffness/Pain Relief)

Frequently Asked Questions (FAQ)

Common questions about Superquin (FAQ)

Q: Is Superquin similar to other medicines I've seen advertised?

A: Superquin is classified as a fluoroquinolone, a group of anti-infective agents. Medicines within this class share structural and mechanistic features by targeting essential bacterial DNA enzymes. Differences exist, however, between specific agents within this large class.

Q: What is the difference between Superquin and [Name of Similar Drug]?

A: Official information describes Superquin as a prodrug, meaning the compound you take (Prulifloxacin) is converted inside the body into the fully active agent (Ulifloxacin). This design feature is noted as a distinction from many other antibiotics.

Q: Is Superquin considered a strong medicine?

A: Superquin is officially classified as a potent, broad-spectrum anti-infective agent belonging to the fluoroquinolone family. This indicates that the drug is designed to address a wide range of susceptible bacteria, according to its pharmacological profile.

Q: Is it okay to take Superquin for a long period of time?

A: Regulatory documents define a maximum duration of use for Superquin, such as up to 10 days for certain conditions. The prescribed duration of use should adhere to the necessary course of treatment for approved indications, as it is not intended for long-term or indefinite use.

Q: How long does Superquin stay in the system after the last dose?

A: The pharmacokinetics section of the official product information describes how the drug is processed. The active component, Ulifloxacin, has a specific elimination half-life that determines the time required for measurable concentrations to leave the body after the final dose.

Q: What is Superquin's classification (e.g., antibiotic, painkiller, etc.)?

A: Superquin is classified as a fluoroquinolone antibiotic. Its primary function is described as an anti-infective agent intended to address susceptible bacterial pathogens.

Q: Do I need a special prescription or monitoring to get Superquin?

A: Superquin is a prescription-only medicine. Regulatory documents include warnings that may require careful monitoring of certain high-risk patients, such as the elderly or those with existing kidney issues, due to the risk of serious side effects.

Q: Are there any known interactions between Superquin and herbal supplements?

A: Official drug documents focus on warning against taking the medicine with products containing multivalent cations like iron and calcium, which are often found in vitamin and mineral supplements. The label does not typically list specific interactions with non-mineral herbal products.

Q: Can Superquin affect my ability to drive or operate machinery?

A: Official product information advises caution because side effects such as dizziness, confusion, or visual disturbances may occur with Superquin use. These effects could potentially impair a person's ability to drive safely or operate machinery.

Q: Is it normal to feel a bit tired when starting Superquin?

A: Official safety reviews of the fluoroquinolone antibiotic class, which includes Superquin, have documented fatigue or tiredness as a potential side effect that is documented in official safety reviews.

Q: Does Superquin need to be taken at a specific time of day?

A: The medicine is intended for once-daily use. The prescribed use involves taking the medicine around the same time each day, a practice intended to maintain consistent levels of the active substance in the body throughout the treatment course.

Q: Why do official documents advise caution when using Superquin with alcohol?

A: While regulatory labels may not list a mandatory, direct contraindication with alcohol, official information may include a general caution regarding alcohol, as it could exacerbate common side effects such as dizziness and stomach upset, or generally impact the patient’s condition during therapy.

Q: Is Superquin a relatively new medicine?

A: Official pharmacological and scientific literature describes Superquin as a modern, third-generation fluoroquinolone antibiotic, reflecting its place in the development timeline of this class of anti-infective agents.

Q: Can Superquin affect my eyesight or vision?

A: Official safety information for the fluoroquinolone class notes that visual disturbances or problems with eyesight may occur as a potential side effect. This is one of the systemic effects documented in the overall safety profile.

Q: What is the proper way to discontinue Superquin?

A: Superquin is an antibiotic intended to be taken for the full duration prescribed to maximize the likelihood of a successful treatment outcome. However, regulatory guidance states that if a patient experiences signs of a serious side effect, such as tendon pain, the medicine is to be stopped immediately and medical attention sought.

Q: Can Superquin be split or crushed if I have trouble swallowing pills?

A: The official instructions indicate that the dose must be divided for patients with severe kidney problems, suggesting the film-coated tablet can be split for that specific purpose. Standard administration instructions indicate that the tablets should not be crushed or otherwise altered.

Q: Can I drink coffee or tea while taking Superquin?

A: Official warnings emphasize avoiding separation from milk, calcium-fortified beverages, and mineral supplements. Regulatory documents do not contain a specific official warning about the general consumption of plain coffee or tea.

Q: Are there any common vitamins that should not be taken with Superquin?

A: Yes, official regulatory documents specifically require a time separation between taking Superquin and any products containing multivalent cations, such as common iron or calcium supplements, as these can interfere with the absorption of the medicine.

Q: Do the official safety warnings for Superquin include a Black Box Warning?

A: Yes. Fluoroquinolones, the drug class Superquin belongs to, are associated with a Boxed Warning (often called a Black Box Warning) in the US regulatory system. This warning highlights the risk of serious and potentially permanent adverse effects on the body, particularly the tendons and nervous system.

Q: Is Superquin meant to be taken 'as needed' or regularly?

A: Superquin is a prescription antibiotic intended to be taken on a regular, once-daily schedule for a defined period of time. It is not an 'as needed' medicine.

Q: Are there any differences in the effect of Superquin based on age?

A: Regulatory documents indicate that the prescribed dose must be adjusted for adults with severe kidney impairment. Also, specific warnings about the risk of tendon damage are highlighted for elderly patients (over 60), reflecting age-related differences in risk profile.

Q: What happens if I miss taking a dose of Superquin?

A: Official guidance instructs that a missed dose should be taken immediately unless it is judged to be close to the time of the next scheduled dose. In that case, the missed dose should be skipped entirely, and the regular schedule resumed.

Q: Can pregnant women or those planning to become pregnant use Superquin?

A: Regulatory documents explicitly state that use of Superquin is absolutely prohibited during pregnancy and breastfeeding. While there is no explicit instruction regarding the planning-to-become-pregnant phase, the general restriction on use during pregnancy is an important consideration.

Q: What if Superquin doesn't seem to be working for me after a few weeks?

A: The duration of treatment is limited to a relatively short course (e.g., up to 10 days for certain conditions). If symptoms related to the infection do not improve during or shortly after the approved treatment course, consulting the prescriber is the recommended next step.

Q: Has Superquin been approved in Europe, or just the US?

A: Official information and regulatory history show that Superquin is recognized and approved in several European and Asian markets. However, documents suggest the medicine has not been approved for use in the United States.

Q: Is Superquin considered a first-line treatment for its main indication?

A: Due to the risk of serious side effects, regulatory authorities have implemented restrictions on the use of fluoroquinolones, including Superquin. This positioning means the drug may be reserved for use when alternative antibacterial agents are not appropriate, according to established clinical guidelines.

Q: Does taking Superquin with or without food change anything?

A: Official administration instructions emphasize separating the dose from products containing multivalent cations, such as certain antacids or mineral supplements. Regulatory documents do not typically mandate taking the medicine with or without a general meal.

Q: Is Superquin safe to use if I have a history of liver problems?

A: While the official label mandates specific dose adjustments for severe kidney problems, it does not specify the same for liver problems. Caution is typically noted for patients with compromised organ function. However, mandatory dose adjustments for Superquin are not explicitly listed based solely on a history of liver issues in the official labeling.

Q: Is it true that Superquin can interact with heart medications?

A: Yes. Regulatory documents include a cardiac risk warning that Superquin has the potential to prolong the QT interval, which is an electrical change in the heart. This is especially relevant to patients taking certain heart rhythm medications or those with known heart conditions.

Q: What evidence exists about Superquin's effectiveness in real-world settings?

A: In addition to controlled clinical trials, studies have been conducted to examine the effectiveness of Superquin in real-life clinical practice, including its impact on patient-reported outcomes for specific bacterial infections.

How should Superquin be stored and disposed of?

Superquin (Prulifloxacin) must be stored and handled according to the instructions provided in its official regulatory labeling to ensure product stability.

Official Storage Conditions

Requirement Type Labeled Constraint
Temperature Store at controlled room temperature (e.g., 20 C to 25 C or not exceeding 30 C).
Environmental Product must be protected from light, heat, and moisture and kept in a dry location.
Container Must be stored in its original container and kept tightly closed to maintain product integrity.
Child Safety Keep this medicine out of the sight and reach of children and pets.

Disposal Requirements

Unused or expired Superquin must be discarded in accordance with local regulations for pharmaceutical waste. Disposal should prioritize official drug take-back programs or DEA-authorized collectors where available. If no take-back option is available and the drug is not on the FDA's flush list, official guidance requires mixing the medicine with an undesirable substance (such as dirt or cat litter) in a sealed bag before placing it in the trash. The medicine should not be disposed of in wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Superquin found in:

A-Z Index: